Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
The safety assessment is based on the independent safety profiles of each compound (GLP-1 medications through extensive FDA trials, BPC-157 through decades of preclinical research), their non-overlapping mechanisms, and growing clinical experience from physicians who prescribe both
What the evidence shows The approval rests primarily on OASIS 4, a phase 3 randomised, double-blind, placebo-controlled trial of 307 adults with overweight or obesity and without diabetes, randomised 2:1 to oral semaglutide 25 mg or placebo for 64 weeks alongside lifestyle support (Wharton et al., 2025)
could still lead to a larger impact on overall health spending in the U.S
You are welcome to come in anytime to mark your progress on the InBody
NICE obesity guidance
If youre already taking medications for HS, such as biologics, you should talk to your doctor about whether adding a GLP-1 drug is safe
US$ 29.76
US$ 25.17
US$ 28.57
